's () James Barder talks to Proactive London's Katie Pilbeam about the announcement made today on the regulatory progress in the US.
Barder also hints upon significant commercial interest for its erectile dysfunction gel with talks ongoing with a growing number of potential partners.
Med3000 is an over-the-counter treatment and as a consequence would have huge commercial potential. Barder is confident the negotiations with the FDA will be satisfactorily and is planning for a Q1 confirmation.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE